Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pfizer

24.19
-0.0500-0.21%
Post-market: 24.16-0.0300-0.12%19:59 EDT
Volume:39.53M
Turnover:958.03M
Market Cap:137.53B
PE:17.49
High:24.42
Open:24.35
Low:24.08
Close:24.24
Loading ...

Pfizer’s Bold Clinical Trials Could Boost Stock Performance

TIPRANKS
·
28 Jun

3 No-Brainer Stocks to Buy for Under $100 Right Now

Motley Fool
·
28 Jun

Weekend Talk Shows/June 28-29

Reuters
·
28 Jun

Pfizer’s New Clinical Study on PF-07985631: A Potential Game-Changer for Kidney Disease

TIPRANKS
·
28 Jun

BUZZ-Gilead, cancer test makers up after U.S. top court ruling on preventative coverage

Reuters
·
27 Jun

Harvard Is Asking Corporations to Fill Its Federal Funding Gap -- WSJ

Dow Jones
·
27 Jun

Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)

Dow Jones
·
27 Jun

US CDC panel broadly recommends flu shots free from thimerosal

Reuters
·
27 Jun

Pfizer’s Promising Clinical Trial for Relapsed Refractory Multiple Myeloma

TIPRANKS
·
27 Jun

Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma Treatment

TIPRANKS
·
27 Jun

US CDC panel votes in favor of Merck's RSV antibody drug

Reuters
·
26 Jun

US Cdc Advisory Panel Votes 5-1 in Favor of Children 18 Years & Younger Receiving Seasonal Flu Vaccine Only in Single Dose Forms That Are Free From Thimerosal

THOMSON REUTERS
·
26 Jun

Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies

Reuters
·
26 Jun

Pfizer Announces Positive Phase 3 Results for HYMPAVZI in Hemophilia A or B with Inhibitors, Showcasing Significant Reduction in Bleeding Rates

Reuters
·
26 Jun

Pfizer Inc - to Initiate Regulatory Filings for Hympavzi

THOMSON REUTERS
·
26 Jun

Pfizer Inc - Hympavzi Generally Well-Tolerated With No Deaths or Thromboembolic Events

THOMSON REUTERS
·
26 Jun

Pfizer Inc - Hympavzi Shows 93% Reduction in Annualized Bleeding Rate

THOMSON REUTERS
·
26 Jun

Pfizer Inc - Hympavzi Demonstrates Superiority in Reducing Bleeding Outcomes

THOMSON REUTERS
·
26 Jun

Pfizer Announces Positive Topline Phase 3 Results for Hympavzi™ in Hemophilia a or B With Inhibitors

THOMSON REUTERS
·
26 Jun

Pfizer Inc - Declares $0.43 Third-Quarter 2025 Dividend

THOMSON REUTERS
·
26 Jun